Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

AKRLKKLAKKIWKWK

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references1 reference

3D coordinates·PEPstrMOD predictionpredicted

PEPstrMOD prediction·reference selected·length 15 aa·confidence predicted

Link	Method	Confidence	Match
Open	PEPstrMOD model	predicted	15 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors15 aa · pI 12.1 · GRAVY -1.19

Length: 15 aa
Monoisotopic mass: 1924.26 Da
Average mass: 1925.48 Da
Net charge at pH 7.4: 8.00
Estimated pI: 12.14
GRAVY: -1.193
KD-positive residues: 33.3%
Aromatic residues: 13.3%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 1.73
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

8.98

pH 5

8.04

pH 6

8.00

pH 7.4

7.94

pH 9

7.18

pH 12

0.18

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Basic (K,R,H)

8 · 53.3%

Hydrophobic aliphatic (A,V,I,L,M)

5 · 33.3%

Aromatic (F,W,Y)

2 · 13.3%

Top residues

K746.7%A213.3%L213.3%W213.3%R16.7%I16.7%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

6-12

KLAKKIW

GRAVY -0.357

Most hydrophilic window

9-15

KKIWKWK

GRAVY -1.843

9 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

2-13

KRLKKLAKKIWK

μH 2.41 · charge 7.0

12 aa window

1-12

AKRLKKLAKKIW

μH 2.15 · charge 6.0

12 aa window

3-14

RLKKLAKKIWKW

μH 2.08 · charge 6.0

12 aa window

4-15

LKKLAKKIWKWK

μH 1.80 · charge 6.0

15 aa window

1-15

AKRLKKLAKKIWKWK

μH 1.73 · charge 8.0

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

W · pos 12, 14

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 1.73100°/residue · 15 aa

Hydrophobic moment1.73

Mean K-D hydropathy-1.19

Approx. net charge+8

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

91.33

Instability index

14.1

At or below 40 — predicted stable in vitro.

Boman index

2.05 kcal/mol

Molar extinction coefficient (280 nm)

11,000 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 5.71

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Metabolic & Proteolytic Stability

1 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Degradation occured initially after 10 min	Interpret as reported	HPLC · human · Human serum	Result: Qualitative or narrative result · Molecular form: ATLPF0025155 · Dose/window: 128, 64, 32, 16, 8, 4, 2, 1, and 0.5 μM · Human serum protease · In Vitro · Source: Primary reference linked	Reference

Excretion / Persistence

1 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation Remaining 100% more than 120min	Interpret as reported	stability	Result: Qualitative or narrative result · Molecular form: ATLPF0025155 · Source: Primary reference linked	Reference

Toxicity / Safety

13 records

What safety, toxicity, or tolerability evidence is attached?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scope% cytotoxicity % hemolysis

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

% hemolysis7 records · 7 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0 %	Eligible when experimental context matches	Human erythrocytes · Human erythrocytes · human · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Source record
2	0.3 %	Eligible when experimental context matches	Sheep erythrocytes · Sheep erythrocytes · sheep · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
3	0 %	Eligible when experimental context matches	Sheep erythrocytes · Sheep erythrocytes · sheep · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
4	0 %	Eligible when experimental context matches	Sheep erythrocytes · Sheep erythrocytes · sheep · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
5	0.7 %	Eligible when experimental context matches	Sheep erythrocytes · Sheep erythrocytes · sheep · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
6	0.3 %	Eligible when experimental context matches	Sheep erythrocytes · Sheep erythrocytes · sheep · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
7	0.2 %	Eligible when experimental context matches	Sheep erythrocytes · Sheep erythrocytes · sheep · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference

% cytotoxicity6 records · 6 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	6.1 %	Eligible when experimental context matches	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
2	0 %	Eligible when experimental context matches	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
3	4.2 %	Eligible when experimental context matches	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
4	10.4 %	Eligible when experimental context matches	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
5	0 %	Eligible when experimental context matches	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
6	11.7 %	Eligible when experimental context matches	Human keratinocytes HaCat · Human keratinocytes HaCat · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference

Evidence landscape

15 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

0 evidence records

Metabolic & Proteolytic Stability

1 evidence record

Excretion / Persistence

1 evidence record

Toxicity / Safety

13 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Hemolysis Percent Observation

Cytotoxicity Percent Observation

Half Life

Serum Plasma Stability

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Cell / safety model

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrix

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Toxicity / Safety Safety	Cytotoxicity Percent Observation	6.1 %	Reported point value	Eligible when experimental context matches	Human keratinocytes HaCat · human	Not specified	Reference Primary reference linked
2	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	Observation Degradation occured initially after 10 min	Qualitative or narrative result	Interpret as reported	HPLC · human · Human serum	Dose/window: 128, 64, 32, 16, 8, 4, 2, 1, and 0.5 μM · Protease: Human serum protease · In Vitro	Reference Primary reference linked
3	Toxicity / Safety Safety	Cytotoxicity Percent Observation	0 %	Reported point value	Eligible when experimental context matches	Human keratinocytes HaCat · human	Not specified	Reference Primary reference linked
4	Toxicity / Safety Safety	Hemolysis Percent Observation	0.3 %	Reported point value	Eligible when experimental context matches	Sheep erythrocytes · sheep · RBC	Not specified	Reference Primary reference linked
5	Toxicity / Safety Safety	Hemolysis Percent Observation	0 %	Reported point value	Eligible when experimental context matches	Sheep erythrocytes · sheep · RBC	Not specified	Reference Primary reference linked
6	Toxicity / Safety Safety	Cytotoxicity Percent Observation	4.2 %	Reported point value	Eligible when experimental context matches	Human keratinocytes HaCat · human	Not specified	Reference Primary reference linked
7	Toxicity / Safety Safety	Hemolysis Percent Observation	0 %	Reported point value	Eligible when experimental context matches	Sheep erythrocytes · sheep · RBC	Not specified	Reference Primary reference linked
8	Toxicity / Safety Safety	Cytotoxicity Percent Observation	10.4 %	Reported point value	Eligible when experimental context matches	Human keratinocytes HaCat · human	Not specified	Reference Primary reference linked
9	Toxicity / Safety Safety	Hemolysis Percent Observation	0.7 %	Reported point value	Eligible when experimental context matches	Sheep erythrocytes · sheep · RBC	Not specified	Reference Primary reference linked
10	Excretion / Persistence Persistence	Half Life	Observation Remaining 100% more than 120min	Qualitative or narrative result	Interpret as reported	stability	Not specified	Reference Primary reference linked

1–10 / 15

Identity & reference map

15 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary2 reference groups

Identity type: canonical sequence
Reported notation: 0
Reference groups: 2
Measurements: 15
ATL peptide ID: ATLPC0023033

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 15

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 15

Different notation

Reported notation does not resolve to the current display sequence.

0 / 15

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

15 / 15

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

AKRLKKLAKKIWKWK

Reported names

No distinct human-readable aliases are exposed.

Reference map2 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	PersistenceSafetyStability Cytotoxicity Percent Observation, Half Life, Hemolysis Percent Observation, Serum Plasma Stability	No reported alias	14 identity 14 evidence
Source record Open	Safety Hemolysis Percent Observation	No reported alias	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0023033
Identity type: canonical sequence
ADMET endpoints: 4
Evidence records: 15
Reference groups: 2
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0023033

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0023033' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0025155

—

Notation only

Link

Method

Confidence

Match

Open

PEPstrMOD model

predicted

15 aa

Value

Analysis use

Assay / model

Result context

Reference

Observation

Degradation occured initially after 10 min

Interpret as reported

HPLC · human · Human serum

Result: Qualitative or narrative result · Molecular form: ATLPF0025155 · Dose/window: 128, 64, 32, 16, 8, 4, 2, 1, and 0.5 μM · Human serum protease · In Vitro · Source: Primary reference linked